Teachers Retirement System of The State of Kentucky Cuts Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Teachers Retirement System of The State of Kentucky reduced its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 16.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 22,371 shares of the biopharmaceutical company’s stock after selling 4,260 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Celldex Therapeutics were worth $1,208,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Teacher Retirement System of Texas acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at about $331,000. Barclays PLC increased its holdings in Celldex Therapeutics by 82.2% in the third quarter. Barclays PLC now owns 39,768 shares of the biopharmaceutical company’s stock valued at $2,147,000 after buying an additional 17,943 shares in the last quarter. BlackRock Inc. lifted its position in shares of Celldex Therapeutics by 16.0% during the 3rd quarter. BlackRock Inc. now owns 3,133,770 shares of the biopharmaceutical company’s stock valued at $169,191,000 after acquiring an additional 433,120 shares during the period. Principal Financial Group Inc. increased its position in shares of Celldex Therapeutics by 11.4% in the third quarter. Principal Financial Group Inc. now owns 93,428 shares of the biopharmaceutical company’s stock valued at $5,044,000 after buying an additional 9,563 shares in the last quarter. Finally, TD Asset Management Inc. grew its stake in Celldex Therapeutics by 38.7% in the 3rd quarter. TD Asset Management Inc. now owns 62,329 shares of the biopharmaceutical company’s stock valued at $3,365,000 after acquiring an additional 17,400 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

CLDX stock opened at $31.91 on Friday. The firm’s 50-day simple moving average is $39.53 and its 200 day simple moving average is $43.76. Celldex Therapeutics, Inc. has a fifty-two week low of $15.37 and a fifty-two week high of $57.20.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, November 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.09). Celldex Therapeutics had a negative return on equity of 22.71% and a negative net margin of 891.70%. The firm had revenue of $0.15 million during the quarter, compared to the consensus estimate of $1.70 million. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.

Separately, Jefferies Financial Group started coverage on shares of Celldex Therapeutics in a research note on Friday, September 17th. They issued a “buy” rating and a $66.00 target price for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $53.00.

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 9,500 shares of Celldex Therapeutics stock in a transaction dated Thursday, December 23rd. The stock was sold at an average price of $42.00, for a total transaction of $399,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Sarah Cavanaugh sold 7,323 shares of the company’s stock in a transaction that occurred on Wednesday, December 8th. The shares were sold at an average price of $40.00, for a total transaction of $292,920.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,923 shares of company stock valued at $1,463,359. Company insiders own 2.40% of the company’s stock.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

See Also: How is diluted EPS different from basic EPS?

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.